BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
Copyright: ©Author(s) 2026.
World J Orthop. May 18, 2026; 17(5): 116844
Published online May 18, 2026. doi: 10.5312/wjo.v17.i5.116844
Table 7 Comparison of adverse reactions and remedial indicators between the two patient groups, median (25th-75th percentiles), n (%)
GroupRemedial indicator
Adverse reactions
Sufentanil dose
Number of compressions
PONV
Shivering
Excessive sleepiness
Control (n = 40)81.0 (70.0-91.0)11.0 (8.0-16.0)15 (37.5)7 (17.5)16 (40.0)
LB (n = 40)68.0 (66.0-78.0)a8.0 (5.0-9.0)a6 (15.0)3 (7.5)3 (7.5)
z/χ2 value-2.855-3.3935.2301.82911.665
P value0.0040.0010.0410.3110.001


Write to the Help Desk